Compare MREO & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MREO | SACH |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 40.6M |
| IPO Year | 2017 | 2016 |
| Metric | MREO | SACH |
|---|---|---|
| Price | $0.30 | $0.64 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $1.96 | N/A |
| AVG Volume (30 Days) | ★ 632.5K | 125.4K |
| Earning Date | 11-09-2026 | 11-27-2026 |
| Dividend Yield | N/A | ★ 5.76% |
| EPS Growth | 16.67 | ★ 104.30 |
| EPS | ★ N/A | N/A |
| Revenue | $500,000.00 | ★ $57,500,000.00 |
| Revenue This Year | $59.51 | $94.91 |
| Revenue Next Year | $2,326.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.69 |
| 52 Week High | $2.37 | $1.45 |
| Indicator | MREO | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 13.24 |
| Support Level | $0.27 | N/A |
| Resistance Level | $0.35 | $0.87 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 62.55 | 8.71 |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.